1. Home
  2. ITIC vs RZLT Comparison

ITIC vs RZLT Comparison

Compare ITIC & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Investors Title Company

ITIC

Investors Title Company

HOLD

Current Price

$284.90

Market Cap

517.8M

Sector

Finance

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$4.91

Market Cap

420.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITIC
RZLT
Founded
1972
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
517.8M
420.8M
IPO Year
1995
2011

Fundamental Metrics

Financial Performance
Metric
ITIC
RZLT
Price
$284.90
$4.91
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.67
AVG Volume (30 Days)
46.1K
1.9M
Earning Date
05-04-2026
05-13-2026
Dividend Yield
4.43%
N/A
EPS Growth
13.02
26.32
EPS
3.20
N/A
Revenue
$272,755,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$86.32
N/A
Revenue Growth
5.60
N/A
52 Week Low
$207.73
$1.07
52 Week High
$291.44
$11.46

Technical Indicators

Market Signals
Indicator
ITIC
RZLT
Relative Strength Index (RSI) 60.83 53.68
Support Level $246.61 $2.91
Resistance Level $286.53 $5.42
Average True Range (ATR) 7.07 0.35
MACD -0.88 -0.02
Stochastic Oscillator 69.36 61.35

Price Performance

Historical Comparison
ITIC
RZLT

About ITIC Investors Title Company

Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: